Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hepatology · Cirrhosis of the Liver

Validation & Orientation: Understanding Cirrhosis

At a Glance

Cirrhosis is long-term scarring of the liver that can progress from a compensated stage to decompensation with serious complications. Treating the underlying cause can sometimes stabilize or improve liver function, but liver cancer risk may remain, so lifelong monitoring is important.

Receiving a diagnosis of cirrhosis can feel overwhelming, often bringing up a mix of fear, confusion, and even shame. It is important to know that you are not alone in these feelings. While the term is often associated with alcohol use, cirrhosis is actually the final stage of many different types of long-term liver injury, including viral hepatitis, metabolic issues, and autoimmune conditions [1][2]. Understanding what is happening inside your body and how doctors categorize this condition is the first step toward managing your health with confidence.

The Biology of Scarring

Cirrhosis occurs when your liver is subjected to persistent, long-term injury. In response to this damage, specialized cells in the liver called hepatic stellate cells become “activated.” Normally, these cells store Vitamin A, but when the liver is injured, they transform into a type of cell that produces excessive amounts of fibrosis (scar tissue) [3][4].

Think of this process like a wound-healing reaction that never turns off. As this scar tissue builds up, it distorts the liver’s natural, sponge-like structure, making it stiff and hard. This stiffness creates resistance to blood flowing through the liver from the digestive tract, a condition called portal hypertension [5][6]. This increased pressure is the driving force behind many of the complications associated with advanced liver disease [7].

Two Main Stages: Compensated vs. Decompensated

Doctors generally divide cirrhosis into two main clinical phases to help determine the best course of care:

  • Compensated Cirrhosis: In this stage, the liver is scarred but can still perform its essential functions. You may feel completely well and have no obvious symptoms [8]. Your lab tests, like bilirubin or albumin, may even appear normal [9]. However, normal blood work alone does not mean the cirrhosis is low-risk. The goal in this stage is to treat the underlying cause and prevent the disease from progressing.
  • Decompensated Cirrhosis: This stage is marked by the development of serious complications. The liver can no longer “compensate” for the extensive scarring. Signs of decompensation include ascites (fluid buildup in the abdomen), jaundice (yellowing of the skin or eyes), variceal bleeding (bleeding from swollen veins in the esophagus), or hepatic encephalopathy (confusion or “brain fog” caused by toxin buildup) [8][10].

A critical transition point within the compensated stage is clinically significant portal hypertension (CSPH). Even if you feel fine, if the pressure in your portal vein is high enough (often measured indirectly through liver stiffness or platelet counts), your risk of future complications increases [11][12].

Quick Glossary of Terms

  • CSPH: Clinically Significant Portal Hypertension.
  • Ascites: Fluid buildup in the abdomen.
  • Varices: Swollen veins in the esophagus or stomach that can bleed.
  • HE (Hepatic Encephalopathy): Confusion or sleep-pattern changes due to toxin buildup.
  • MELD & Child-Pugh: Scoring systems doctors use to measure liver disease severity and risk.

Can the Liver Heal?

A common misconception is that cirrhosis is always a “one-way street.” While extensive scarring is often permanent, research shows that liver fibrosis is a dynamic process. If the underlying cause of the injury—such as a virus or a metabolic condition—is successfully treated or removed, the “activated” stellate cells can become quiet again [3][13].

In some cases, the body can break down some of the scar tissue and even regenerate healthy liver cells [14]. This “remodeling” can stabilize your health and, for some, even move them from a decompensated state back to a compensated one [15]. However, recompensation is not a cure. The risk for certain complications, like liver cancer, remains. For this reason, lifelong monitoring and surveillance by a specialist are usually necessary [16][17].

Addressing the Stigma and Emotional Toll

The psychological impact of cirrhosis can be as heavy as the physical symptoms. Many people face a “stigma” associated with liver disease, leading to feelings of isolation or a hesitation to share their diagnosis with others [1]. It is important to recognize that:

  • Stigma is common but unfounded: Many different conditions lead to cirrhosis, and everyone deserves compassionate care regardless of the cause [2][18].
  • Mental health is health: Depression, anxiety, and extreme fatigue are documented medical aspects of cirrhosis and can significantly impact your quality of life [19][20].
  • Support matters: Discussing these feelings with your care team is vital. Support groups, social workers, and mental health professionals can help you navigate the emotional challenges of this journey [21][22].

Note: This page provides an overview of the condition. For specific information on medical emergencies and urgent symptoms, please refer to the ‘Symptoms and Warning Signs’ page.

Common questions in this guide

What is cirrhosis of the liver, and what causes it?
Cirrhosis is long-term scarring caused by ongoing liver injury. It can result from viral hepatitis, metabolic conditions, autoimmune disease, alcohol-related injury, and other chronic causes, so it is not caused only by alcohol.
What is the difference between compensated and decompensated cirrhosis?
In compensated cirrhosis, the liver is scarred but still carries out many essential functions, and a person may have few or no obvious symptoms. Decompensated cirrhosis means serious complications such as abdominal fluid buildup, yellow skin or eyes, bleeding from swollen veins, or confusion have developed.
Can liver scarring from cirrhosis improve?
Treating or removing the cause of liver injury can quiet the process that creates scar tissue, and the body may break down some fibrosis. Health can sometimes stabilize or improve enough to move from decompensated to compensated cirrhosis, but this is not a cure and risks such as liver cancer can remain.
What is clinically significant portal hypertension?
Portal hypertension is increased pressure in the vein system that carries blood from the digestive organs to the liver. In cirrhosis, stiff scar tissue resists blood flow; clinically significant portal hypertension raises the risk of complications, and doctors may look at liver stiffness or platelet counts for indirect signs.
What do MELD and Child-Pugh scores mean?
MELD and Child-Pugh are scoring systems doctors use to estimate how severe liver disease is and assess risk. Your care team must interpret the score or class along with your symptoms, examination, and test results; a single number does not describe your whole health.
How often will I need monitoring with cirrhosis?
Cirrhosis usually requires lifelong follow-up, even if liver function improves or you feel well. Your specialist will set the schedule for monitoring and screening for liver cancer, portal hypertension, and varices based on the cause and stage of your disease.
How can cirrhosis affect mental health?
Cirrhosis can be associated with depression, anxiety, extreme fatigue, sleep problems, and feelings of shame or isolation. Tell your care team about these experiences because support groups, social workers, and mental health professionals can help.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the likely cause of my cirrhosis, and have we ruled out things other than alcohol?
  2. 2.Am I currently considered 'compensated' or 'decompensated,' and what does that mean for my day-to-day life?
  3. 3.What is my current MELD score or Child-Pugh class, and what do these numbers tell us about my liver's health?
  4. 4.Are there signs of 'clinically significant portal hypertension' in my test results, such as my platelet count or liver stiffness?
  5. 5.Is there a specific treatment for the underlying cause of my liver injury that might help my liver start to repair itself?
  6. 6.How often will I need screening for liver cancer or varices, even if my liver health seems to be improving?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life.

    Carol M, Pérez-Guasch M, Solà E, et al.

    PloS one 2022; (17(4)):e0265153 doi:10.1371/journal.pone.0265153.

    PMID: 35385510
  2. 2

    The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.

    Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al.

    JHEP reports : innovation in hepatology 2024; (6(7)):101066 doi:10.1016/j.jhepr.2024.101066.

    PMID: 39022387
  3. 3

    Reversal of liver cirrhosis: current evidence and expectations.

    Jung YK, Yim HJ

    The Korean journal of internal medicine 2017; (32(2)):213-228 doi:10.3904/kjim.2016.268.

    PMID: 28171717
  4. 4

    Pathophysiology of Liver Fibrosis.

    Pinzani M

    Digestive diseases (Basel, Switzerland) 2015; (33(4)):492-7 doi:10.1159/000374096.

    PMID: 26159264
  5. 5

    Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.

    Abraldes JG, Trebicka J, Chalasani N, et al.

    Hepatology (Baltimore, Md.) 2019; (69(3)):1287-1299 doi:10.1002/hep.30314.

    PMID: 30318607
  6. 6

    Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension.

    Li Y, Zhu B, Shi K, et al.

    Frontiers in medicine 2025; (12()):1515400 doi:10.3389/fmed.2025.1515400.

    PMID: 39958826
  7. 7

    Angiogenesis and portal-systemic collaterals in portal hypertension.

    Gana JC, Serrano CA, Ling SC

    Annals of hepatology 2016; (15(3)):303-13 doi:10.5604/16652681.1198799.

    PMID: 27049484
  8. 8

    Key Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications.

    Flamm SL

    The American journal of medicine 2024; (137(10)):929-938 doi:10.1016/j.amjmed.2024.05.015.

    PMID: 38788826
  9. 9

    Towards a new definition of decompensated cirrhosis.

    D'Amico G, Bernardi M, Angeli P

    Journal of hepatology 2022; (76(1)):202-207 doi:10.1016/j.jhep.2021.06.018.

    PMID: 34157322
  10. 10

    Acute and non-acute decompensation of liver cirrhosis.

    McCoy MS, Angeli P, Trebicka J

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(3)):e15861 doi:10.1111/liv.15861.

    PMID: 38426268
  11. 11

    Baveno VII - Renewing consensus in portal hypertension.

    de Franchis R, Bosch J, Garcia-Tsao G, et al.

    Journal of hepatology 2022; (76(4)):959-974 doi:10.1016/j.jhep.2021.12.022.

    PMID: 35120736
  12. 12

    Update on the Evaluation and Management of Portal Hypertension.

    Aitcheson G, Cezar C, John I, John BV

    Gastroenterology & hepatology 2021; (17(12)):569-578.

    PMID: 35465066
  13. 13

    Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression.

    Mendoza YP, Tsouka S, Semmler G, et al.

    Journal of hepatology 2024; (81(6)):983-994 doi:10.1016/j.jhep.2024.06.028.

    PMID: 38944391
  14. 14

    Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.

    Khan S, Saxena R

    Advances in anatomic pathology 2021; (28(6)):408-414 doi:10.1097/PAP.0000000000000312.

    PMID: 34326286
  15. 15

    Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

    Sanyal AJ, Anstee QM, Trauner M, et al.

    Hepatology (Baltimore, Md.) 2022; (75(5)):1235-1246 doi:10.1002/hep.32204.

    PMID: 34662449
  16. 16

    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.

    Lens S, Baiges A, Alvarado-Tapias E, et al.

    Journal of hepatology 2020; (73(6)):1415-1424 doi:10.1016/j.jhep.2020.05.050.

    PMID: 32535060
  17. 17

    Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?

    D'Ambrosio R, Colombo M

    Liver international : official journal of the International Association for the Study of the Liver 2016; (36(6)):783-90 doi:10.1111/liv.13106.

    PMID: 26936383
  18. 18

    Cross-sectional study on stigma and motivation to adhere to lifestyle modification among vulnerable populations with fatty liver disease.

    Medina SP, Kim RG, Magee C, et al.

    Obesity science & practice 2023; (9(6)):581-589 doi:10.1002/osp4.688.

    PMID: 38090690
  19. 19

    Anxiety in cirrhosis: a prospective study on prevalence and development of a practical screening nomogram.

    Dang TT, Patel K, Farhat K, et al.

    European journal of gastroenterology & hepatology 2022; (34(5)):553-559 doi:10.1097/MEG.0000000000002301.

    PMID: 35421020
  20. 20

    Impact of depressive symptoms and hepatic encephalopathy on health-related quality of life in cirrhotic hepatitis C patients.

    Barboza KC, Salinas LM, Sahebjam F, et al.

    Metabolic brain disease 2016; (31(4)):869-80 doi:10.1007/s11011-016-9817-y.

    PMID: 27032930
  21. 21

    Perceived Stigma in Patients with Autoimmune Hepatitis.

    Naftaly JP, Feldman ECH, Greenley RN

    Journal of clinical psychology in medical settings 2024; (31(2)):455-464 doi:10.1007/s10880-023-09983-z.

    PMID: 38127091
  22. 22

    Continued alcohol consumption and hepatic encephalopathy determine quality of life and psychosocial burden of caregivers in patients with liver cirrhosis.

    Nagel M, Weidner V, Schulz S, et al.

    Health and quality of life outcomes 2022; (20(1)):23 doi:10.1186/s12955-022-01923-z.

    PMID: 35135582

This cirrhosis overview is for informational purposes only and does not constitute medical advice. Your healthcare team should interpret your MELD or Child-Pugh results and recommend monitoring and treatment for your situation.

Get notified when new evidence is published on cirrhosis of liver.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.